|
1
|
Perlman E, Grosfeld J, Togashi K and
Boccon-Gibod L: Pathology and genetics of tumors of the urinary
system and male genital organs. World Health Organization
Classification of Tumours. 1st edition. IARC Press; Lyon, France;
pp. 48–52. 2004
|
|
2
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gelb AB: Renal cell carcinoma: Current
prognostic factors. Union Internationale Contre le Cancer (UICC)
and the American Joint Committee on Cancer (AJCC). Cancer.
80:981–986. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F,
He Z, Sheng X, Bi F, Cao D, et al: Chinese guidelines on the
management of renal cell carcinoma (2015 edition). Ann Transl Med.
3:2792015.PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie B, Ding Q, Han H and Wu D: miRCancer:
A microRNA-cancer association database constructed by text mining
on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nugent M: microRNA and bone cancer. Adv
Exp Med Biol. 889:201–230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Del Vescovo V and Denti MA: microRNA and
lung cancer. Adv Exp Med Biol. 889:153–177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sui GQ, Fei D, Guo F, Zhen X, Luo Q, Yin S
and Wang H: MicroRNA-338-3p inhibits thyroid cancer progression
through targeting AKT3. Am J Cancer Res. 7:1177–1187.
2017.PubMed/NCBI
|
|
15
|
Zhang G, Zheng H, Zhang G, Cheng R, Lu C,
Guo Y and Zhao G: MicroRNA-338-3p suppresses cell proliferation and
induces apoptosis of non-small-cell lung cancer by targeting
sphingosine kinase 2. Cancer Cell Int. 17:462017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang P, Shao G, Lin X, Liu Y and Yang Z:
MiR-338-3p inhibits the growth and invasion of non-small cell lung
cancer cells by targeting IRS2. Am J Cancer Res. 7:53–63.
2017.PubMed/NCBI
|
|
17
|
Zhang T, Liu W, Zeng XC, Jiang N, Fu BS,
Guo Y, Yi HM, Li H, Zhang Q, Chen WJ and Chen GH: Down-regulation
of microRNA-338-3p promoted angiogenesis in hepatocellular
carcinoma. Biomed Pharmacother. 84:583–591. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin Y, Zhao M, Xie Q, Zhang H, Wang Q and
Ma Q: MicroRNA-338-3p functions as tumor suppressor in breast
cancer by targeting SOX4. Int J Oncol. 47:1594–1602. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xue Q, Sun K, Deng HJ, Lei ST, Dong JQ and
Li GX: MicroRNA-338-3p inhibits colorectal carcinoma cell invasion
and migration by targeting smoothened. Jpn J Clin Oncol. 44:13–21.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li D, Liu X, Lin L, Hou J, Li N, Wang C,
Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits
hepatocellular carcinoma growth and correlates with prognosis of
patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song B, Zhang C, Li G, Jin G and Liu C:
MiR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou Q and Yu Y: Upregulated CDK16
expression in serous epithelial ovarian cancer cells. Med Sci
Monit. 21:3409–3414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li H, Xu Y, Qiu W, Zhao D and Zhang Y:
Tissue miR-193b as a novel biomarker for patients with ovarian
cancer. Med Sci Monit. 21:3929–3934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gai D, Haan E, Scholar M, Nicholl J and Yu
S: Phenotypes of AKT3 deletion: A case report and literature
review. Am J Med Genet A. 167A:174–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dimmeler S, Aicher A, Vasa M, Mildner-Rihm
C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H and
Zeiher AM: HMG-CoA reductase inhibitors (statins) increase
endothelial progenitor cells via the PI 3-kinase/Akt pathway. J
Clin Invest. 108:391–397. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stitt TN, Drujan D, Clarke BA, Panaro F,
Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD and Glass DJ: The
IGF-1/PI3K/Akt pathway prevents expression of muscle
atrophy-induced ubiquitin ligases by inhibiting FOXO transcription
factors. Mol Cell. 14:395–403. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Manning BD, Tee AR, Logsdon MN, Blenis J
and Cantley LC: Identification of the tuberous sclerosis complex-2
tumor suppressor gene product tuberin as a target of the
phosphoinositide 3-kinase/akt pathway. Mol Cell. 10:151–162. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brunet A, Datta SR and Greenberg ME:
Transcription-dependent and-independent control of neuronal
survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol.
11:297–305. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Turner KM, Sun Y, Ji P, Granberg KJ,
Bernard B, Hu L, Cogdell DE, Zhou X, Yli-Harja O, Nykter M, et al:
Genomically amplified Akt3 activates DNA repair pathway and
promotes glioma progression. Proc Natl Acad Sci USA. 112:3421–3426.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim M, Kim YY, Jee HJ, Bae SS, Jeong NY,
Um JH and Yun J: Akt3 knockdown induces mitochondrial dysfunction
in human cancer cells. Acta Biochim Biophys Sin (Shanghai).
48:447–453. 2016. View Article : Google Scholar : PubMed/NCBI
|
